Equifax Inc Q1 2021 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Andrew Owen Nicholas - William Blair & Company L.L.C., Research Division - Analyst : You touched on it a bit in your prepared remarks, but I was hoping you could walk through the i2verify acquisition a bit further. How should we think about it contributing to the TWN database in terms of record count? And then relatedly, can you give us a sense for how many other assets like this are out there that could add records to the database in a meaningful way? Certainly, it seems like these types of deals come with some pretty immediate revenue synergies. So any additional detail on that opportunity set would be helpful.

Question: Andrew Owen Nicholas - William Blair & Company L.L.C., Research Division - Analyst : Great. Makes sense. That's all very helpful. And then for my follow-up, you've mentioned 100 basis point improvement in your Vitality Index expectation a couple of times. I imagine that's primarily a consequence of faster than expected adoption on the new product side. So I was just kind of hoping you could talk about what's driving that specifically through the first couple of months of the year? And then relatedly, what do you think that pickup in adoption means as you think about the Vitality Index in '22 and beyond? And how NPIs are expected to contribute over a longer-term time frame?

Question: Andrew Owen Nicholas - William Blair & Company L.L.C., Research Division - Analyst : No problem. I can't -- not surprised if that would throw anyone off. Yes. My question was just on the Vitality Index and how you might look at 2022 and beyond on that metric, given the faster than expected adoption so far this year? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. APRIL 22, 2021 / 12:30PM, EFX.N - Q1 2021 Equifax Inc Earnings Call